Drugs / Multipeptide Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04688385 | Dec 2020 → Oct 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multipeptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04688385 ↗ |
| Modality | Vaccine | “personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15” NCT04688385 ↗ |
| Route | Subcutaneous | “Participants received three monthly doses of iTAC-XS15-CLL01 (consisting of 300 μg of each peptide plus 50 μg XS15, emulsified in Montanide ISA 51 VG), injected subcutaneously.” PMID 41547362 ↗ Jan 2026 |